Search results for "Radiopharmaceuticals."

showing 10 items of 133 documents

Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy

2015

INTRODUCTION Aim of the study is to evaluate the impact of Cho-PET/CT in decision-making strategy of patients with localized prostate cancer (PC) eligible to definitive radiotherapy (RT). MATERIALS AND METHODS Sixty patients Cho-PET/CT before RT were prospectively enrolled. All patients were treated with volumetric modulated arc therapy with simultaneous integrated boost in 28 fractions. Androgen deprivation therapy was prescribed according to National Comprehensive Cancer Network (NCCN) risk classification. Therapeutic strategy based on the Cho-PET/CT evaluation was compared with the strategy that would have been proposed in case of PET not available and/or not strictly indicated, accordin…

Malemedicine.medical_specialtyRadical treatmentmedicine.medical_treatmentClinical Decision-Making18F-cholineMultimodal ImagingCholineAndrogen deprivation therapyProstate cancerProstateNuclear Medicine and ImagingIntensity-ModulatedMedicineHumansRadiology Nuclear Medicine and imagingRadiation treatment planningTomographyAgedPET-CTProstate cancerRadiotherapybusiness.industryCancerProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseX-Ray ComputedRadiation therapymedicine.anatomical_structurePositron-Emission TomographyRadiologyCho-PET/CT; Prostate cancer; Radical treatment; Radiotherapy; Aged; Choline; Humans; Male; Middle Aged; Multimodal Imaging; Prostatic Neoplasms; Radiopharmaceuticals; Clinical Decision-Making; Positron-Emission Tomography; Radiotherapy Intensity-Modulated; Tomography X-Ray Computed; Radiology Nuclear Medicine and ImagingRadiotherapy Intensity-ModulatedRadiopharmaceuticalsbusinessNuclear medicineRadiologyTomography X-Ray ComputedCho-PET/CT
researchProduct

Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resi…

2018

In vivo pharmacokinetic analysis of [Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from therapeutic activity of [Lu]Lu-PSMA-617 and to predict the maximum permissible activity of [Lu]Lu-PSMA-617 for patients with metastatic castration-resistant prostate carcinoma. Methods Pharmacokinetics of [Sc]Sc-PSMA-617 was evaluated in 5 patients with metastatic castration-resistant prostate carcinoma using dynamic PET/CT, followed by 3 static PET/CT acquisitions and blood sample collection over 19.5 hours, as well as urine sample collection at 2 time points. Total activity measured in source organs by PET imaging, as well as counts per milliliter measured in bloo…

Malemedicine.medical_treatmentUrineLutetiumRadiation Dosageurologic and male genital diseases030218 nuclear medicine & medical imagingCastration-Resistant Prostate CarcinomaHeterocyclic Compounds 1-Ring03 medical and health sciences0302 clinical medicinePharmacokineticsIn vivoPositron Emission Tomography Computed TomographyOrganometallic CompoundsmedicineHumansRadiology Nuclear Medicine and imagingExternal beam radiotherapyNeoplasm MetastasisAgedUrinary bladderbusiness.industryRadiotherapy Planning Computer-AssistedCarcinomaRadiotherapy DosageDipeptidesGeneral MedicineProstate-Specific AntigenProstatic Neoplasms Castration-Resistantmedicine.anatomical_structure030220 oncology & carcinogenesisSample collectionBone marrowRadiopharmaceuticalsbusinessNuclear medicineScandiumClinical Nuclear Medicine
researchProduct

Scandium-44: Benefits of a Long-Lived PET Radionuclide Available from the 44Ti/44Sc Generator System

2011

(44)Ti/(44)Sc radionuclide generators are of interest for molecular imaging. The 3.97 hours half-life of (44)Sc and its high positron branching of 94.27% may stimulate the application of (44)Sc-labeled PET radiopharmaceuticals. This review describes the current status of (44)Ti production, (44)Ti/(44)Sc radionuclide generator development, post-processing of generator eluates towards medical application, identification of ligands adequate to Sc(III) co-ordination chemistry, proof-of-principle labeling of (44)Sc-DOTA-octreotides, investigation of in vitro and in vivo parameters, and initial applications for molecular imaging - both in small animals and humans.

Materials scienceTransplantation HeterologousMice Nudechemistry.chemical_elementHeterocyclic Compounds 1-RingMicePositronDrug StabilityNickelNuclear ReactorsmedicineAnimalsHumansRadiology Nuclear Medicine and imagingCation Exchange ResinsScandiumChelating AgentsMice nudeRadioisotopesTitaniumPharmacologyRadionuclidemedicine.diagnostic_testRadionuclide GeneratorsLiver NeoplasmsNeoplasms ExperimentalTransplantationchemistryPositron emission tomographyPositron-Emission TomographyPuromycinAdsorptionRadiopharmaceuticalsRadionuclide GeneratorMolecular imagingScandiumHalf-LifeNuclear chemistryCurrent Radiopharmaceuticals
researchProduct

Measurement of cerebral ABCC1 transport activity in wild-type and APP/PS1-21 mice with positron emission tomography

2020

Previous data suggest a possible link between multidrug resistance-associated protein 1 (ABCC1) and brain clearance of beta-amyloid (Aβ). We used PET with 6-bromo-7-[11C]methylpurine ([11C]BMP) to measure cerebral ABCC1 transport activity in a beta-amyloidosis mouse model (APP/PS1-21) and in wild-type mice aged 50 and 170 days, without and with pretreatment with the ABCC1 inhibitor MK571. One hundred seventy days-old-animals additionally underwent [11C]PiB PET scans to measure Aβ load. While baseline [11C]BMP PET scans detected no differences in the elimination slope of radioactivity washout from the brain (kelim) between APP/PS1-21 and wild-type mice of both age groups, PET scans after MK…

Mice TransgenicNeuroimaging03 medical and health sciencesAmyloid beta-Protein PrecursorMice0302 clinical medicineMethylpurineAlzheimer Diseasemental disordersmedicinePresenilin-1Animals030304 developmental biology0303 health sciencesmedicine.diagnostic_testbiologyTransport activityChemistryWild typeOriginal ArticlesMolecular biologyMice Inbred C57BLDisease Models AnimalNeurologyPositron emission tomographyPositron-Emission TomographyABCC1biology.proteinFemaleNeurology (clinical)Multidrug Resistance-Associated Protein 1Multidrug Resistance-Associated ProteinsRadiopharmaceuticalsCardiology and Cardiovascular Medicine030217 neurology & neurosurgeryJournal of Cerebral Blood Flow & Metabolism
researchProduct

Impact of systematic whole-body 18F-fluorodeoxyglucose PET/CT on the management of patients suspected of infective endocarditis: the prospective mult…

2021

AbstractBackgroundDiagnostic and patients’ management modifications induced by whole-body 18F-FDG-PET/CT had not been evaluated so far in prosthetic valve (PV) or native valve (NV) infective endocarditis (IE)-suspected patients.MethodsIn sum, 140 consecutive patients in 8 tertiary care hospitals underwent 18F-FDG-PET/CT. ESC-2015-modified Duke criteria and patients’ management plan were established jointly by 2 experts before 18F-FDG-PET/CT. The same experts reestablished Duke classification and patients’ management plan immediately after qualitative interpretation of 18F-FDG-PET/CT. A 6-month final Duke classification was established.ResultsAmong the 70 PV and 70 NV patients, 34 and 46 wer…

Microbiology (medical)medicine.medical_specialty[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging18F-FDG-PET/CT030204 cardiovascular system & hematologyTertiary careDuke criteriaFluorodeoxyglucose PET03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemFluorodeoxyglucose F18[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesPositron Emission Tomography Computed Tomographydiagnostic impactmedicineHumans030212 general & internal medicineProspective Studiespatient managementProsthetic valveEndocarditisbusiness.industryinfective endocarditismedicine.diseaseDiagnostic classification3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInfectious Diseases[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/ImagingNative valveInfective endocarditisHeart Valve Prosthesis[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesRadiologyRadiopharmaceuticalsWhole bodybusiness
researchProduct

Past, present and future of 68Ge/68Ga generators.

2013

(68)Ga represents one of the very early radionuclides applied to positron emission tomography (PET) imaging at a time when even the wording PET itself was not established. Today it faces a renaissance in terms of new (68)Ge/(68)Ga radionuclide generators, sophisticated (68)Ga radiopharmaceuticals, and state-of-the-art clincial diagnoses via positron emission tomography/computed tomography (PET/CT). Thanks to the pioneering achievement of radiochemists in Obninsk, Russia, a new type of (68)Ge/(68)Ga generators became commercially available in the first years of the 21st century. Generator eluates based on hydrochloric acid provided "cationic" (68)Ga instead of "inert" (68)Ga-complexes, openi…

Multimodal imagingmedicine.medical_specialtyRadiationmedicine.diagnostic_testRadionuclide GeneratorsThe RenaissanceComputed tomographyGallium RadioisotopesEngineering physicsMultimodal ImagingX ray computedPositron emission tomographyPositron-Emission TomographymedicineMedical physicsRadionuclide GeneratorRadiopharmaceuticalsTomography X-Ray ComputedApplied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
researchProduct

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.

2014

Objective To analyze the feasibility of laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal intra-operative chemotherapy (SCS + HIPEC) in a retrospective series of isolated platinum sensitive recurrent ovarian cancer. Methods We retrospectively evaluated a consecutive series of ovarian cancer patients with isolated platinum sensitive relapse. Isolated relapse was defined as the presence of a single nodule, in a single anatomic site. In all cases the presence of isolated relapse was assessed at pre-operative FDG-PET/CT scan, and confirmed with staging laparoscopy performed immediately before SCS + HIPEC. Results 84 women with platinum sensitive relapse recei…

OVARIAN CANEROrganoplatinum Compoundsmedicine.medical_treatmentdrug therapy/pathology/surgery/therapyCarcinoma Ovarian EpithelialMultimodal ImagingCohort StudiesObstetrics and gynaecologyNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsInfusions ParenteralNeoplasms Glandular and EpithelialLaparoscopyadministration /&/ dosageTomographyRandomized Controlled Trials as TopicOvarian Neoplasmsmedicine.diagnostic_testObstetrics and GynecologyGlandular and EpithelialMiddle AgedDebulkingCombined Modality TherapyIsolated platinum sensitive relapseX-Ray ComputedOxaliplatinPhase III as TopicOncologyFemalediagnostic usemedicine.drugmedicine.medical_specialtyInfusionsAged Antineoplastic Combined Chemotherapy Protocols; administration /&/ dosage Cisplatin; administration /&/ dosage Clinical Trials; Phase II as Topic Clinical Trials; Phase III as Topic Cohort Studies Combined Modality Therapy Female Fluorodeoxyglucose F18; diagnostic use Humans Hyperthermia; Induced; methods Infusions; Parenteral Middle Aged Minimally Invasive Surgical Procedures Multimodal Imaging Neoplasms; Glandular and Epithelial; drug therapy/pathology/surgery/therapy Organoplatinum Compounds; administration /&/ dosage Ovarian Neoplasms; drug therapy/pathology/surgery/therapy Positron-Emission Tomography Radiopharmaceuticals; diagnostic use Randomized Controlled Trials as Topic Retrospective Studies Tomography; X-Ray Computed ocal; pathologyocalmethodsClinical Trials Phase II as TopicMinimally invasive surgeryOvarian cancerFluorodeoxyglucose F18ParenteralmedicineHumansMinimally Invasive Surgical ProceduresClinical TrialsHyperthermiaAgedRetrospective StudiesCisplatinChemotherapySeries (stratigraphy)HIPECbusiness.industryPhase II as TopicInducedHyperthermia Inducedmedicine.diseaseOxaliplatinSurgeryRoboticSettore MED/40 - GINECOLOGIA E OSTETRICIAClinical Trials Phase III as TopicPositron-Emission TomographyLaparoscopypathologyNeoplasm Recurrence LocalCisplatinRadiopharmaceuticalsbusinessOvarian cancerTomography X-Ray Computed
researchProduct

Genotyping analysis and 18FDG uptake in breast cancer patients: a preliminary research

2013

Background: Diagnostic imaging plays a relevant role in the care of patients with breast cancer (BC). Positron Emission Tomography (PET) with 18F-fluoro-2-deoxy-D-glucose (FDG) has been widely proven to be a clinical tool suitable for BC detection and staging in which the glucose analog supplies metabolic information about the tumor. A limited number of studies, sometimes controversial, describe possible associations between FDG uptake and single nucleotide polymorphisms (SNPs). For this reason this field has to be explored and clarified. We investigated the association of SNPs in GLUT1, HIF-1a, EPAS1, APEX1, VEGFA and MTHFR genes with the FDG uptake in BC. Methods: In 26 caucasian individu…

OncologyCancer Researchmedicine.medical_specialtyPathologydbSNPGenotypePET-CTSingle-nucleotide polymorphismStandardized uptake valueBreast NeoplasmsGene mutationMultimodal ImagingPolymorphism Single NucleotideBreast cancerBreast cancerFluorodeoxyglucose F18Internal medicinemedicineHumansPET-CTSUVpvcbiologybusiness.industryResearchGlucose analogSUVmaxSingle nucleotide polymorphismsmedicine.diseaseSingle nucleotide polymorphismBreast cancer Single nucleotide polymorphisms PET-CT SUVmax SUVpvcOncologyMethylenetetrahydrofolate reductasePositron-Emission Tomographybiology.proteinFemaleRadiopharmaceuticalsbusinessTomography X-Ray Computed
researchProduct

Positron emission tomography and neoadjuvant therapy of breast cancer

2011

The increasing use of neoadjuvant therapy for breast cancer has led to the development of early surrogate markers of response. Positron emission tomography (PET) allows noninvasive study of fundamental biologic processes in the tumor; furthermore, PET provides various markers to assess tumor response early in the course of therapy. Numerous studies have shown that changes in tumor glucose metabolism during therapy are significantly correlated with final response and patient outcome. Moreover, new PET tracers that are currently being developed or under evaluation, providing specific information on tumor characteristics or receptor expression, will assist the development of new targeted antic…

OncologyCancer Researchmedicine.medical_treatmentReceptor expressionTumor response030218 nuclear medicine & medical imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineAntineoplastic Agent0302 clinical medicineMonoclonalPet tracerHumanizedAdjuvantNeoadjuvant therapyComputingMilieux_MISCELLANEOUSAntibodies Monoclonal Humanized; Antineoplastic Agents; Biomarkers Tumor; Breast Neoplasms; Chemotherapy Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Radiopharmaceuticals; Trastuzumab; Neoadjuvant Therapy; Positron-Emission Tomography; Cancer Research; Oncology; Medicine (all)Tumormedicine.diagnostic_testMedicine (all)General MedicineNeoadjuvant Therapy3. Good healthOncologyChemotherapy AdjuvantPositron emission tomography030220 oncology & carcinogenesisRadiopharmaceuticalFemaleBreast NeoplasmHumanmedicine.medical_specialtyAntineoplastic AgentsBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineAntibodies Monoclonal HumanizedAntibodies[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciencesBreast cancerFluorodeoxyglucose F18Internal medicineBiomarkers TumormedicineChemotherapyHumansbusiness.industryTrastuzumabmedicine.diseasePositron-Emission TomographyRadiopharmaceuticalsbusinessBiomarkers
researchProduct

Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer

2017

Background: Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively short physical half-life of gallium-68 this positron emitter precludes prolonged acquisition periods, as required for pre-therapeutic dosimetry or intraoperative applications. In this context, the positron emitter scandium-44 is an attractive alternative for PET imaging. We report the synthesis of [44Sc…

OncologyMalemedicine.medical_specialtytheranostics.Medicine (miscellaneous)Context (language use)SpleenGallium RadioisotopesLutetiumurologic and male genital diseases030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancerHeterocyclic Compounds 1-Ring0302 clinical medicineInternal medicinePositron Emission Tomography Computed TomographyLNCaPmedicineDosimetryHumansRadiometryPharmacology Toxicology and Pharmaceutics (miscellaneous)AgedRadioisotopesUrinary bladderChemistrybusiness.industryDipeptidesProstate-Specific Antigenmedicine.diseaseprostate cancerPSMA-617scandium-44Small intestineProstatic Neoplasms Castration-Resistantmedicine.anatomical_structurePET030220 oncology & carcinogenesisAbsorbed doseRadiopharmaceuticalsNuclear medicinebusinessScandiumResearch PaperHalf-LifeTheranostics
researchProduct